You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Baker Bros. Advisors||27,372,236||0||27,372,236||0||27,372,236||22.1%|
|Baker Bros. Advisors (GP)||27,372,236||0||27,372,236||0||27,372,236||22.1%|
|Felix J. Baker||27,372,236||9.||27,372,236||11.||27,372,236||22.1%|
|Julian C. Baker||27,372,236||9.||27,372,236||11.||27,372,236||22.1%|
Follow Julian Baker And Felix Baker's Baker Bros. Advisors
Page 1 of 9 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
INFORMATION TO BE INCLUDED IN STATEMENTS
TO RULE 13d-l(a) AND AMENDMENTS THERETO
TO RULE 13d-2(a)
(Amendment No. 10)*
ACADIA Pharmaceuticals Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
Alexandra A. Toohey
Chief Financial Officer
Baker Bros. Advisors LP
667 Madison Avenue, 21st Floor
New York, NY 10065
address and telephone number of person authorized to receive notices and communications)
May 15, 2017
(Date of event which requires filing of this statement)
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.
(Continued on the following pages)
(Page 1 of 9 Pages)
|*||The remainder of this cover page shall be filled out |
for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.